Medigene AG
XETRA:MDG1
Intrinsic Value
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. [ Read More ]
The intrinsic value of one MDG1 stock under the Base Case scenario is 4.21 EUR. Compared to the current market price of 1.44 EUR, Medigene AG is Undervalued by 66%.
Valuation Backtest
Medigene AG
Run backtest to discover the historical profit from buying and selling MDG1 stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medigene AG
Current Assets | 12.4m |
Cash & Short-Term Investments | 12.4m |
Earnings Waterfall
Medigene AG
Revenue
|
4.6m
EUR
|
Operating Expenses
|
-8.9m
EUR
|
Operating Income
|
-4.3m
EUR
|
Other Expenses
|
58k
EUR
|
Net Income
|
-4.3m
EUR
|
Free Cash Flow Analysis
Medigene AG
MDG1 Profitability Score
Profitability Due Diligence
Medigene AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Medigene AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
MDG1 Solvency Score
Solvency Due Diligence
Medigene AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Medigene AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDG1 Price Targets Summary
Medigene AG
According to Wall Street analysts, the average 1-year price target for MDG1 is 2.67 EUR with a low forecast of 2.25 EUR and a high forecast of 3.15 EUR.
Shareholder Return
MDG1 Price
Medigene AG
Average Annual Return | -28.88% |
Standard Deviation of Annual Returns | 15.18% |
Max Drawdown | -84% |
Market Capitalization | 42.4m EUR |
Shares Outstanding | 29 475 200 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 121 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one MDG1 stock under the Base Case scenario is 4.21 EUR.
Compared to the current market price of 1.44 EUR, Medigene AG is Undervalued by 66%.